RJA
GANX icon

Raymond James & Associates’s Gain Therapeutics GANX Stock Holding History

Raymond James & Associates’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-260,019
Closed -$980K – 4014
2024
Q1 		$980K Buy
260,019
+236,231
+993% +$979K ﹤0.01% 2605
2023
Q4 		$77.7K Sell
23,788
-10,012
-30% -$27.8K ﹤0.01% 3669
2023
Q3 		$111K Buy
33,800
+400
+1% +$1.52K ﹤0.01% 3579
2023
Q2 		$150K Buy
33,400
+13,400
+67% +$65.4K ﹤0.01% 3549
2023
Q1 		$96.4K Sell
20,000
-4,000
-17% -$16.4K ﹤0.01% 3658
2022
Q4 		$75.1K Hold
24,000
– – ﹤0.01% 3676
2022
Q3 		$78K Buy
+24,000
New +$90.2K ﹤0.01% 3649

Other funds holding GANX

TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $847M AUM 29.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James & Associates's GANX Position: Q2 2024 in Review

Raymond James & Associates sold out of Gain Therapeutics (GANX) in Q2 2024, closing a stake of 260,019 shares — an estimated $980K sold.

Raymond James & Associates first reported a position in GANX in Q3 2022 and held it in 7 quarters. The position peaked at $980K in Q1 2024. 28 funds tracked by Wall St. Rank hold GANX as of Q2 2024.

  • Raymond James & Associates reported no remaining Gain Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 260,019 Gain Therapeutics shares in Q2 2024, an estimated $980K.
  • Raymond James & Associates first reported a position in Gain Therapeutics in Q3 2022 and held it in 7 quarters.
  • Raymond James & Associates's Gain Therapeutics position peaked at $980K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.